Detection of severity in Alzheimer’s disease (AD) using computational modeling

Kim, Hyun-Jo

doi:10.6026/97320630014259

Cited by 4 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The absence of proper sleep and sleeplessness can result in abnormal brain activity and some enhanced formation, like amyloid-related Alzheimer's. Getting undiagnosed sleep issues could also create a person too much susceptible to Alzheimer's [13].…”

Section: Poor Sleepmentioning

confidence: 99%

Test

Injeti¹

2023

Fut J. Pharm & H. Sci

View full text Add to dashboard Cite

show abstract

Section: Poor Sleepmentioning

confidence: 99%

Test

Injeti¹

2023

Fut J. Pharm & H. Sci

View full text Add to dashboard Cite

show abstract

“…The development of neurofibrillary tangles in neurons is a second feature of AD. Specifically, neurofibrillary tangles are formed when tau protein, a protein involved in microtubule formation, undergoes chemical modification (abnormally folded and phosphorylated [118]. Although extremely rare, they account for less than 1% of the cases of three of these specific genetic mutations from chromosome 21, presenilin-1 [PS 1] on chromosome 14 and presenilin-2 [PS 2] on chromosome 1 have been detected in patients with early onset familial autosomal dominant AD [98][99][100].…”

Section: Alzheimer's Diseasementioning

confidence: 99%

Microfluidics for Brain Endothelial-Astrocytic Interactions

Sanapathi,

Vipparthi,

Sosnik

et al. 2023

Preprint

View full text Add to dashboard Cite

With the approval of the FDA Modernization Act 2.0, the pharmaceutical industry is poised to expand its research components with a plethora of alternative models, including organ-on-microfluidic chips in pharma and biotechnology, resulting in a personalized approach. Microfluidics opens new possibilities for the study of cell biology, especially for a better understanding of cell-cell interactions and the pathophysiology of neurodegenerative diseases in vitro and use these models to assess the efficacy of novel therapies. These thumb-sized organ-on-a-chip systems have the potential to reduce animal testing and replace simple 2D culture systems. Restoring critical aspects of endothelial-brain immune cell communication in a biomimetic system using microfluidics may accelerate the process of central nervous system (CNS) drug discovery and improve our understanding of the mechanisms of multiple neurodegenerative diseases. These organ-on-chip technologies can be used to optimize drug targets and assess drug efficacy and toxicity in real-time, which can significantly help minimize animal testing requirements, as authorized by the recent FDA Act. Recent advances in modeling cell-to-cell communication in the CNS are described in this review. This Review initially summarizes the fundamental advantages of microfluidic systems in creating a compartmentalized cell culture for the complex three-dimensional architectures of neural tissue cells such as neurons, glial cells, and endothelial cells, and their recapitulation of spatiotemporal biophysicochemical gradients and mechanical microenvironments. Brain endothelial cell-astroglia-on-a-chip models with a focus on neurodegenerative diseases such Alzheimer's disease, Parkinson's disease, and Huntington's disease and amyotrophic lateral sclerosis is introduced. Then, the current limitations of these microfluidic devices and strategies to overcome them are discussed.

show abstract